Progress in immunotherapy for small cell lung cancer

Small-cell lung cancer (SCLC) is a special type of lung cancer that belongs to highly aggressive neuroendocrine tumors. At present, radiotherapy and chemotherapy remain the mainstay of treatment for SCLC. Progress in targeted therapies for SCLC with driver mutations has been slow, and these therapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Dong, Xie, Bing, Yang, Yong, Yan, Peng, Liang, Sheng-Nan, Lin, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450814/
https://www.ncbi.nlm.nih.gov/pubmed/32874950
http://dx.doi.org/10.5306/wjco.v11.i6.370
_version_ 1783574867241598976
author Zhao, Dong
Xie, Bing
Yang, Yong
Yan, Peng
Liang, Sheng-Nan
Lin, Qiang
author_facet Zhao, Dong
Xie, Bing
Yang, Yong
Yan, Peng
Liang, Sheng-Nan
Lin, Qiang
author_sort Zhao, Dong
collection PubMed
description Small-cell lung cancer (SCLC) is a special type of lung cancer that belongs to highly aggressive neuroendocrine tumors. At present, radiotherapy and chemotherapy remain the mainstay of treatment for SCLC. Progress in targeted therapies for SCLC with driver mutations has been slow, and these therapies are still under investigation in preclinical or early-phase clinical trials, and research on antiangiogenic tyrosine kinase inhibitors (e.g., anlotinib) has achieved some success. Immunotherapy is becoming an important treatment strategy for SCLC after radiotherapy and chemotherapy. In this article we review the recent advances in immunotherapy for SCLC.
format Online
Article
Text
id pubmed-7450814
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-74508142020-08-31 Progress in immunotherapy for small cell lung cancer Zhao, Dong Xie, Bing Yang, Yong Yan, Peng Liang, Sheng-Nan Lin, Qiang World J Clin Oncol Minireviews Small-cell lung cancer (SCLC) is a special type of lung cancer that belongs to highly aggressive neuroendocrine tumors. At present, radiotherapy and chemotherapy remain the mainstay of treatment for SCLC. Progress in targeted therapies for SCLC with driver mutations has been slow, and these therapies are still under investigation in preclinical or early-phase clinical trials, and research on antiangiogenic tyrosine kinase inhibitors (e.g., anlotinib) has achieved some success. Immunotherapy is becoming an important treatment strategy for SCLC after radiotherapy and chemotherapy. In this article we review the recent advances in immunotherapy for SCLC. Baishideng Publishing Group Inc 2020-06-24 2020-06-24 /pmc/articles/PMC7450814/ /pubmed/32874950 http://dx.doi.org/10.5306/wjco.v11.i6.370 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Minireviews
Zhao, Dong
Xie, Bing
Yang, Yong
Yan, Peng
Liang, Sheng-Nan
Lin, Qiang
Progress in immunotherapy for small cell lung cancer
title Progress in immunotherapy for small cell lung cancer
title_full Progress in immunotherapy for small cell lung cancer
title_fullStr Progress in immunotherapy for small cell lung cancer
title_full_unstemmed Progress in immunotherapy for small cell lung cancer
title_short Progress in immunotherapy for small cell lung cancer
title_sort progress in immunotherapy for small cell lung cancer
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450814/
https://www.ncbi.nlm.nih.gov/pubmed/32874950
http://dx.doi.org/10.5306/wjco.v11.i6.370
work_keys_str_mv AT zhaodong progressinimmunotherapyforsmallcelllungcancer
AT xiebing progressinimmunotherapyforsmallcelllungcancer
AT yangyong progressinimmunotherapyforsmallcelllungcancer
AT yanpeng progressinimmunotherapyforsmallcelllungcancer
AT liangshengnan progressinimmunotherapyforsmallcelllungcancer
AT linqiang progressinimmunotherapyforsmallcelllungcancer

Ejemplares similares